Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)

General Information

Summary The main objective of this clinical study is to evaluate the safety of XS005 cell which contains Natural Killer (NK) cells and culture-expanded injection; to determine the maximum tolerated dose . Furthermore, initial efficacy will be examined.
Description Treatment on this study includes eight XS005 cell infusions over an 16 week period. The study will evaluate the safety, feasibility and maximum tolerated dose (MTD) of XS005 cell using a 3+3 study design . The total study duration will be 2 years.
Clinical trials phase Phases 1/2
Start date (estimated) 2023-10-29
End date (estimated) 2025-12-29
Clinical feature
Label glioblastoma
Description A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes.

Administrative Information

NCT number NCT06147505
ICTRP weblink
Other study identifiers
Name XS-005
Source weblink
Public contact
Public email
First name Yulun
Last name Huang
Phone +86 130 1388 9432
Sponsors Dushu Lake Hospital Affiliated to Soochow University


Which differentiated cell type is used
Label natural killer cell
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Recruiting
Estimated number of participants 30